Insecticides India Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/a4llgeuuawduy9t3ejtsg49e.pdf

Key Takeaways


Revenue Performance & Seasonal Dynamics

Rajesh Aggarwal: "Last year it was very bad situation in this period. Generally, the month of August is almost similar to the month of July. But last year it was 50% off July... This year, I believe that we will be touching July figures actually in the month of August. If we are able to do that then we should be able to beat the last year in two months itself, last year Q2 in two months itself."

Margin Structure & Product Portfolio Strategy

Rajesh Aggarwal: "It is our continuous goal of increasing the margins by 100 bps year on year. I'll not say that 100 bps will be sustainable year on year."

Export Challenges

Rajesh Aggarwal: "The currency worldwide has deteriorated too much and the countries do not have the dollars to pay. So, this has slowed down our exports because people are shaking to avoid the -- they're avoiding to place a big order because of the non-consistency of price or the heavy price increase and they are converting these big orders into small, small orders."

New Products & Innovation Pipeline

Rajesh Aggarwal: "Companies worldwide claim that one new discovery takes more than INR 1000 crore to launch and this type of time, we have set up this JV in 2013 and we are sitting in 2023, already 10 years are gone. I'll be launching my first product by 2025 or '26 and majority of the products, two, three products which are there in line they will come by 2030."

Capacity Expansion & CapEx


Guidance & Commitments

CommitmentSpecificsTimeline
Q2 revenue growthBeat Q1 growth (20%+)Q2 FY23
Q2 EBITDA marginIncrease of ~100 bps, driven by better Maharatna mixQ2 FY23
Full-year EBITDA marginIncrease of ~100 bps for the year as a wholeFY23
Full-year revenue growth18–20%FY23
Export revenue₹150 crore (toned down from ₹200 crore), crossing last year's ~₹130–140 croreFY23
Chopanki plantFull operations startingAugust
Dahej plant expansionOperations starting around Diwali (delayed ~1 month from September)October
Q2 product launchesIzuki, Supremo, Stunner (3 products)Q2 FY23
Full-year product launches8–9 new products, subject to registration timelinesFY23
JV first new-discovery productFirst product launch2025 or 2026
JV majority pipeline products2–3 products to launchBy 2030
IIL Biologicals subsidiaryBusiness to startNext fiscal
Full-year CapExApproximately ₹30–40 croreFY23

Key Metrics

MetricQ1 FY23
Revenue₹560 cr, +19.5% YoY
EBITDA₹58 cr, +10.5% YoY
Revenue growth19.5%, driven by new product launches and volume growth; price hike contributed 7–8%
EBITDA margin guidance (Q2 FY23)+100 bps targeted improvement over Q2 FY22
EBITDA margin guidance (full year FY23)+100 bps targeted improvement, though not sustainable year on year
Export revenue target (full year FY23)₹150 cr, toned down from original ₹200 cr target due to international challenges; last year exports were ₹130–140 cr
Full-year revenue growth target20%
CapEx (full year FY23)₹30–40 cr, primarily for Dahej and Chopanki plant completions
Focused Maharatnas products11 products, part of a 35-product Maharatnas range contributing 65% of brand revenue
Products crossing ₹50 cr revenue (FY23)More than half a dozen products expected
New product launches planned (FY23)8–9 products; 2 launched in Q1 (Torry, Shinwa), 3 planned for Q2 (Izuki, Supremo, Stunner)
Patents filedMore than 32 filed, approximately half received
GLP accreditation52nd in India across all sectors